Cargando…
Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease
Increasing evidence suggests that Parkinson’s disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique—Subtype and Stage Inference (SuStaIn) — to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344958/ https://www.ncbi.nlm.nih.gov/pubmed/37443179 http://dx.doi.org/10.1038/s41531-023-00556-3 |
_version_ | 1785072977395580928 |
---|---|
author | Zhou, Cheng Wang, Linbo Cheng, Wei Lv, JinChao Guan, Xiaoujun Guo, Tao Wu, Jingjing Zhang, Wei Gao, Ting Liu, Xiaocao Bai, Xueqin Wu, Haoting Cao, Zhengye Gu, Luyan Chen, Jingwen Wen, Jiaqi Huang, Peiyu Xu, Xiaojun Zhang, Baorong Feng, Jianfeng Zhang, Minming |
author_facet | Zhou, Cheng Wang, Linbo Cheng, Wei Lv, JinChao Guan, Xiaoujun Guo, Tao Wu, Jingjing Zhang, Wei Gao, Ting Liu, Xiaocao Bai, Xueqin Wu, Haoting Cao, Zhengye Gu, Luyan Chen, Jingwen Wen, Jiaqi Huang, Peiyu Xu, Xiaojun Zhang, Baorong Feng, Jianfeng Zhang, Minming |
author_sort | Zhou, Cheng |
collection | PubMed |
description | Increasing evidence suggests that Parkinson’s disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique—Subtype and Stage Inference (SuStaIn) — to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We enrolled 228 PD patients and 119 healthy controls with comprehensive assessments of olfactory, autonomic, cognitive, sleep, and emotional function. The integrity of substantia nigra (SN), locus coeruleus (LC), amygdala, hippocampus, entorhinal cortex, and basal forebrain were assessed using diffusion and neuromelanin-sensitive MRI. SuStaIn model with above clinical and neuroimaging variables as input was conducted to identify PD subtypes. An independent dataset consisting of 153 PD patients and 67 healthy controls was utilized to validate our findings. We identified two distinct PD subtypes: subtype 1 with rapid eye movement sleep behavior disorder (RBD), autonomic dysfunction, and degeneration of the SN and LC as early manifestations, and cognitive impairment and limbic degeneration as advanced manifestations, while subtype 2 with hyposmia, cognitive impairment, and limbic degeneration as early manifestations, followed later by RBD and degeneration of the LC in advanced disease. Similar subtypes were shown in the validation dataset. Moreover, we found that subtype 1 had weaker levodopa response, more GBA mutations, and poorer prognosis than subtype 2. These findings provide new insights into the underlying disease biology and might be useful for personalized treatment for patients based on their subtype. |
format | Online Article Text |
id | pubmed-10344958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-103449582023-07-15 Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease Zhou, Cheng Wang, Linbo Cheng, Wei Lv, JinChao Guan, Xiaoujun Guo, Tao Wu, Jingjing Zhang, Wei Gao, Ting Liu, Xiaocao Bai, Xueqin Wu, Haoting Cao, Zhengye Gu, Luyan Chen, Jingwen Wen, Jiaqi Huang, Peiyu Xu, Xiaojun Zhang, Baorong Feng, Jianfeng Zhang, Minming NPJ Parkinsons Dis Article Increasing evidence suggests that Parkinson’s disease (PD) exhibits disparate spatial and temporal patterns of progression. Here we used a machine-learning technique—Subtype and Stage Inference (SuStaIn) — to uncover PD subtypes with distinct trajectories of clinical and neurodegeneration events. We enrolled 228 PD patients and 119 healthy controls with comprehensive assessments of olfactory, autonomic, cognitive, sleep, and emotional function. The integrity of substantia nigra (SN), locus coeruleus (LC), amygdala, hippocampus, entorhinal cortex, and basal forebrain were assessed using diffusion and neuromelanin-sensitive MRI. SuStaIn model with above clinical and neuroimaging variables as input was conducted to identify PD subtypes. An independent dataset consisting of 153 PD patients and 67 healthy controls was utilized to validate our findings. We identified two distinct PD subtypes: subtype 1 with rapid eye movement sleep behavior disorder (RBD), autonomic dysfunction, and degeneration of the SN and LC as early manifestations, and cognitive impairment and limbic degeneration as advanced manifestations, while subtype 2 with hyposmia, cognitive impairment, and limbic degeneration as early manifestations, followed later by RBD and degeneration of the LC in advanced disease. Similar subtypes were shown in the validation dataset. Moreover, we found that subtype 1 had weaker levodopa response, more GBA mutations, and poorer prognosis than subtype 2. These findings provide new insights into the underlying disease biology and might be useful for personalized treatment for patients based on their subtype. Nature Publishing Group UK 2023-07-13 /pmc/articles/PMC10344958/ /pubmed/37443179 http://dx.doi.org/10.1038/s41531-023-00556-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhou, Cheng Wang, Linbo Cheng, Wei Lv, JinChao Guan, Xiaoujun Guo, Tao Wu, Jingjing Zhang, Wei Gao, Ting Liu, Xiaocao Bai, Xueqin Wu, Haoting Cao, Zhengye Gu, Luyan Chen, Jingwen Wen, Jiaqi Huang, Peiyu Xu, Xiaojun Zhang, Baorong Feng, Jianfeng Zhang, Minming Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease |
title | Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease |
title_full | Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease |
title_fullStr | Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease |
title_full_unstemmed | Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease |
title_short | Two distinct trajectories of clinical and neurodegeneration events in Parkinson’s disease |
title_sort | two distinct trajectories of clinical and neurodegeneration events in parkinson’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344958/ https://www.ncbi.nlm.nih.gov/pubmed/37443179 http://dx.doi.org/10.1038/s41531-023-00556-3 |
work_keys_str_mv | AT zhoucheng twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT wanglinbo twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT chengwei twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT lvjinchao twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT guanxiaoujun twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT guotao twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT wujingjing twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT zhangwei twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT gaoting twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT liuxiaocao twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT baixueqin twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT wuhaoting twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT caozhengye twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT guluyan twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT chenjingwen twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT wenjiaqi twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT huangpeiyu twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT xuxiaojun twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT zhangbaorong twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT fengjianfeng twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease AT zhangminming twodistincttrajectoriesofclinicalandneurodegenerationeventsinparkinsonsdisease |